<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03760276</url>
  </required_header>
  <id_info>
    <org_study_id>Voriconazole_CYP2C19</org_study_id>
    <nct_id>NCT03760276</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen</brief_title>
  <official_title>A Pilot Study to Evaluate the Appropriateness of the Voriconazole Dosing Regimen Based on the Population Pharmacokinetic Model and the Influence of Sex on the Pharmacokinetics of Voriconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study was performed to evaluate the appropriateness of the voriconazole dosing
      regimen based on the population pharmacokinetic model and the influence of sex on the
      pharmacokinetics of voriconazole
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Actual">October 28, 2018</completion_date>
  <primary_completion_date type="Actual">October 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Day 1 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours, Day 5 12 hours, Day 6 0, 12 hours, Day 7 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Pharmacokinetic sampling after administration of drugs from day 1 to day 7</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve from the time of dosing to the last measurable concentration (AUClast)</measure>
    <time_frame>Day 1 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours, Day 5 12 hours, Day 6 0, 12 hours, Day 7 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours</time_frame>
    <description>Pharmacokinetic sampling after administration of drugs from day 1 to day 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphisms of CYP2C9 and CYP3A4</measure>
    <time_frame>Day 1 0 hour</time_frame>
    <description>Exploratory evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic safety marker of miRNA-122</measure>
    <time_frame>Day 1 0 hour, Day 5 12 hour, Day 7 12 hour</time_frame>
    <description>Exploratory safety evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability evaluation by monitoring adverse events (number of subjects and cases)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination (list of current medications)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination (list of any symptoms or pain)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination (Medical and surgical history)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital signs (body temperature °C)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital signs (blood pressure mmHg)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital signs (pulse (heart rate, beats per minute))</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Vital signs (breathing rate (respiratory rate, beats per minute))</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability evaluation by 12-lead ECG (P wave, PR interval, QRS complex, J-point, ST segment, T wave, Corrected QT interval, U wave)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with abnormal laboratory values (hematologic, chemical, urine)</measure>
    <time_frame>Day 1 to Day 12</time_frame>
    <description>Safety and tolerability evaluation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Fungal Infection</condition>
  <arm_group>
    <arm_group_label>Voriconazole TBD mg tablet orally, every 12 hours for 7 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole Oral Product (Vfend®)</intervention_name>
    <description>To be determined mg of Voriconazole (Vfend®, anti-fungal agent)</description>
    <arm_group_label>Voriconazole TBD mg tablet orally, every 12 hours for 7 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those who have been informed of the nature of the trial and have voluntarily agreed to
             participate in this study and have signed an IRB approved consent before all screening
             tests

          -  Healthy Korean male and female volunteers aged 20 to 45

          -  Those with a body weight of 50 kg or more and less than 90 kg and a body mass index
             (BMI) of 18 or more and less than 27 (BMI(kg/m2) = body weight (kg)/{height(m)}2

          -  CYP2C19 EM or PM

        Exclusion Criteria:

          -  Subjects with clinical evidence of significant respiratory, circulatory, renal,
             hepatic, endocrine, blood, neuropsychiatric, skeletal or other chronic diseases,
             alcohol or drug addiction

          -  Subjects with a history of gastrointestinal disorders (Crohn's disease, ulcers, acute
             or chronic pancreatitis, etc.) or gastrointestinal surgery (excluding simple cecal
             surgery or hernia surgery) that may affect the absorption of the test drug

          -  Those with a history of substance abuse within the last 2 months

          -  Those who have taken any prescribed medicines or herbal medicines within 2 weeks prior
             to the date of the first medicines, or those taking any general medicines (OTC) or
             vitamin preparations (eligible if the other conditions are reasonable according to the
             judgment of the investigator)

          -  Those who donate blood within 30 days before the date of the first dose or who have
             participated in the clinical study of other clinical trial drugs or marketed drugs
             within 3 months

          -  Those who have had significant adverse reactions such as hypersensitivity reactions to
             azole drugs including drugs for clinical research

          -  Those who are not planning on or planning to have a pregnancy during the trial and are
             not able to use a recognized method of contraception (eg, sterilization surgery of the
             person and partner, intrauterine contraceptive device, or diaphragm contraception
             (such as diaphragm or condom use)

          -  Persons who are continuously drinking (21 units / week, 1 unit = 10 g of pure alcohol)
             or who can not abstain from 3 days before the first dose to the end of the clinical
             trial

          -  Those who smoked more than 10 cigarettes per day for the last 3 months or who can not
             quit smoking 3 days before the first dose

          -  Those who consume grapefruit / caffeine-containing food within 3 days of the first
             dose or who cannot be prohibited during the clinical study period

          -  Screening tests for urine pregnancy (β-hCG) positive or lactating women

          -  Those with genetic problems such as galactose intolerance, Lapp lactase deficiency, or
             glucose-galactose malabsorption.

          -  A person who is found to be unsuitable for participation in clinical research due to
             safety laboratory results or other reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital Clinical Trial Center</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://www.sciencedirect.com/science/article/pii/S0924857915004069?via%3Dihub</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 23, 2018</study_first_submitted>
  <study_first_submitted_qc>November 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2018</study_first_posted>
  <last_update_submitted>November 29, 2018</last_update_submitted>
  <last_update_submitted_qc>November 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>SeungHwan Lee</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

